Figure 6. MTORC1/2 inhibition results in a robust treatment response in Fc¹ Apc^fl/+ Pik3ca^H1047R mice.

These mice were allowed to age to ~100 days. At this time-point, the majority of these tumors are invasive cancers. Mice were treated with BEZ235, TAK-228 or control daily by oral gavage. Murine endoscopy was performed at baseline and following 14 days of treatment (A). Percent lumen occlusion was measured for each tumor and the change in percent lumen occlusion shown in a waterfall plot (B). A significant reduction in median change in lumen occlusion was observed with those tumors treated with BEZ235 (−19%) and TAK-228 (−20%) compared to control (+17%; p = 0.02 and p = 0.004, respectively) (B). A similar reduction in phosphorylation of RPS6 was seen after 14 days of treatment with BEZ235 and TAK-228, however a greater reduction in phosphorylation of AKT and 4EBP1 were observed with TAK-228 treatment (C).